Are we witnessing the beginning of a revolution in Alzheimer’s disease management? After years of fruitless hopes in pharmaceutical research, an international team announces another success story Journal of the American Medical Association (James) , in the framework of the international congress in Amsterdam (Netherlands). At the end of a phase 3 trial (the last phase before applying for marketing authorization), researchers are demonstrating the effectiveness of donanemab, an antibody that targets the amyloid proteins involved in the pathology. It is not the first of its kind. Biogen’s aducanumab was authorized in the United States in June 2021 (but highly controversial and “ full of irregularities “, according to the US Congress); then it was the turn of lecanemab (Biogen and Eisai laboratories), in an emergency setting in January 2023, then a few days before the end of the standard procedure.
Donanemab (from lab…
Source: Le Figaro
I am John Sinkler, a professional writer and journalist for Buna Times. I specialize in writing about entertainment-related topics and have been doing so for several years now. My work has been featured on multiple platforms and I’m proud to say that it’s gained recognition from many people in the industry. Aside from working at Buna Times, I also write freelance articles for other publications.